Home> Products> adequate glycemic control

{ "products": [ { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6825c6cc966e2a18bb4b35a6", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPA PIO", "description": "GLIDAPA PIO is a combination oral medication specially formulated to help manage type 2 diabetes mellitus. It combines two powerful antidiabetic agents, dapagliflozin and pioglitazone, to effectively control blood sugar levels. This medication is prescribed to patients when diet and exercise alone do not provide adequate glycemic control. By addressing blood glucose regulation through different mechanisms, GLIDAPA PIO helps reduce the risk of diabetes-related complications and supports overall metabolic health.\n\nKey Ingredients\nDapagliflozin (10mg): A sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by increasing the excretion of glucose through urine.\n\nPioglitazone (15mg): A thiazolidinedione that improves insulin sensitivity by acting on fat, muscle, and liver cells, facilitating better glucose uptake and utilization.\n\nKey Benefits\nHelps maintain stable blood glucose levels in adults with type 2 diabetes.\n\nCombines two complementary mechanisms to enhance blood sugar control.\n\nSupports weight management due to dapagliflozin’s glucose excretion effect.\n\nMay improve insulin sensitivity and reduce insulin resistance.\n\nReduces the risk of diabetes-related complications such as cardiovascular problems when combined with lifestyle changes.\n\nConvenient once-daily tablet formulation.\n\nHow Does It Work?\nDapagliflozin blocks SGLT2 proteins in the kidneys, preventing glucose reabsorption and promoting its elimination through urine, which lowers blood glucose. Pioglitazone acts on insulin-responsive tissues, enhancing the body’s sensitivity to insulin. This dual action helps reduce both insulin resistance and excess blood glucose, providing better overall glycemic control. By targeting different pathways, GLIDAPA PIO offers a synergistic effect to manage type 2 diabetes more effectively.\n\nDirections for Use\nTake GLIDAPA PIO exactly as prescribed by your healthcare provider.\n\nUsually taken once daily, with or without food, at the same time each day.\n\nDo not skip doses or stop the medication without consulting your doctor.\n\nMaintain a balanced diet and regular exercise as advised alongside the medication.\n\nInform your doctor about any other medications you are taking to avoid potential interactions.\n\nSide Effects\nSome patients may experience side effects while taking GLIDAPA PIO, including:\n\nUrinary tract infections or increased urination due to dapagliflozin.\n\nWeight gain or swelling caused by pioglitazone.\n\nRisk of low blood sugar (hypoglycemia) when combined with other antidiabetic drugs.\n\nPossible dizziness or fatigue.\n\nRarely, heart failure or bladder cancer risk (associated with pioglitazone).\n\nIf you notice symptoms like excessive thirst, sudden weight gain, swelling, shortness of breath, or any allergic reactions, seek medical advice immediately.", "price": 255.0, "discountamount": 77.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medication inform", "pioglitazone risk", "regular exercise", "balanced diet", "doctor maintain", "glucose uptake", "notice symptoms", "antidiabetic drugs", "swelling caused", "advised alongside", "skip doses", "healthcare provider", "effectively directions", "synergistic effect", "glycemic control", "cardiovascular problems", "complementary mechanisms", "fat muscle", "diabetesrelated complications", "insulin resistance", "bodys sensitivity", "glidapa pio", "urine pioglitazone 15mg", "taking glidapa pio", "bladder cancer risk", "improve insulin sensitivity", "improves insulin sensitivity", "glidapa pioglidapa pio", "dapagliflozin weight gain", "increased urination due", "urinary tract infections", "experience side effects", "insulinresponsive tissues enhancing", "liver cells facilitating" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2114, "imageuri": "https://productimages.withfloats.com/actual/6825c6ce65488af627fb2e46.png", "tileimageuri": "https://productimages.withfloats.com/tile/6825c6ce65488af627fb2e46.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-15T10:49:48.361Z", "updatedon": "2025-05-15T10:50:30.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glidapa-pio/2114", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Dapagliflozin 10mg and pioglitazone 15mg tablets", "category": "DIABETIC RANGE", "tags": [ "Dapagliflozin, pioglitazone combination", "Dapagliflozin, pioglitazone combination", "Dapagliflozin Pioglitazone CDSCO" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "681c5e9e5a26e4010ea42029", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ST-GLIPTIN M 100/ 1000", "description": "ST-GLIPTIN M 100/1000 is an advanced oral antidiabetic medication designed for the effective management of Type 2 Diabetes Mellitus. This powerful combination of Sitagliptin (100 mg) and Metformin Hydrochloride (1000 mg) offers dual action in controlling elevated blood glucose levels, especially in patients who do not respond adequately to metformin or sitagliptin alone. It is intended for adults and is generally used in conjunction with diet and exercise to enhance glycemic control.\n\nKey Ingredients\nSitagliptin (100 mg)\nSitagliptin is a DPP-4 (Dipeptidyl Peptidase-4) inhibitor that increases the levels of incretin hormones, which help regulate blood sugar by increasing insulin release and decreasing glucagon levels.\n\nMetformin Hydrochloride (1000 mg)\nMetformin belongs to the biguanide class of antidiabetics. It works by reducing the amount of sugar produced by the liver and improves the body’s sensitivity to insulin, facilitating better glucose utilization.\n\nKey Benefits\nHelps reduce both fasting and postprandial (after-meal) blood glucose levels effectively\nImproves overall glycemic control in patients with Type 2 diabetes\nCombines two different mechanisms of action for better diabetes management\nMinimizes the risk of hypoglycemia compared to other antidiabetic therapies\nMay support weight neutrality or slight weight loss in diabetic individuals\n\nHow Does It Work?\nST-GLIPTIN M 100/1000 works through a synergistic mechanism by combining two effective antidiabetic agents:\n\nSitagliptin enhances the levels of incretin hormones, which help the pancreas produce more insulin and reduce the secretion of glucagon, especially when blood sugar is high.\nMetformin reduces hepatic glucose production and increases insulin sensitivity, which helps the body use glucose more efficiently.\nTogether, these agents provide comprehensive blood sugar control by addressing multiple physiological pathways involved in glucose metabolism.\n\nDirections for Use\nTake ST-GLIPTIN M 100/1000 exactly as prescribed by your physician.\nIt is typically taken once or twice daily with meals to reduce gastrointestinal side effects and optimize absorption.\nSwallow the tablet whole with water. Do not crush or chew the tablet.\nMaintain a balanced diet and follow an active lifestyle for best results.\nRegular blood sugar monitoring is essential to assess effectiveness and make any necessary dosage adjustments.\n\nSide Effects\nCommon side effects may include nausea, diarrhea, stomach upset, or headache.\nSome individuals may experience respiratory tract infections, sore throat, or a runny nose.\nLactic acidosis is a rare but serious side effect associated with high-dose metformin—seek immediate medical attention if symptoms like unusual fatigue, muscle pain, difficulty breathing, or abdominal discomfort occur.\nAllergic reactions such as rash, itching, or swelling are uncommon but possible.\nAlways inform your doctor of any persistent or bothersome side effects for timely intervention.", "price": 225.0, "discountamount": 68.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "1001000 works", "100 1000stgliptin", "work stgliptin", "balanced diet", "tablet maintain", "diabetic individuals", "sitagliptin 100 mg", "timely intervention", "rash itching", "medical attention", "highdose metforminseek", "assess effectiveness", "active lifestyle", "pancreas produce", "synergistic mechanism", "antidiabetic therapies", "hypoglycemia compared", "glycemic control", "biguanide class", "incretin hormones", "respond adequately", "powerful combination", "insulin facilitating", "sugar produced", "side effect", "bodys sensitivity", "effective management", "blood sugar", "increases insulin sensitivity", "regulate blood sugar", "glucose metabolism directions", "increasing insulin release", "bothersome side effects", "diabetes management minimizes", "optimize absorption swallow", "slight weight loss", "support weight neutrality" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2107, "imageuri": "https://productimages.withfloats.com/actual/681c5e9f5e6dd8f19a0309c3.png", "tileimageuri": "https://productimages.withfloats.com/tile/681c5e9f5e6dd8f19a0309c3.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-08T07:34:54.516Z", "updatedon": "2025-05-08T07:35:36.782Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/st-gliptin-m-100-1000/2107", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "sitagliptin and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin and Metformin hydrochloride tablets Uses in Hindi", "sitagliptin and metformin hydrochloride tablets 50/1000 uses in hindi", "sitagliptin and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668d24ff75f1701d34699e32", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE 80 ", "description": "GLICLAGLAZE 80 \nGliclazide (80mg)\nOverview\nGLICLAGLAZE 80 is an oral medication containing Gliclazide at a dosage of 80 mg. Gliclazide belongs to the class of drugs known as sulfonylureas and is primarily used to manage type 2 diabetes mellitus. It helps control blood sugar levels by stimulating the release of insulin from the pancreatic beta cells. GLICLAGLAZE 80 is an effective treatment option for individuals who require oral hypoglycemic therapy to maintain optimal blood glucose levels.\n\nBenefits of Gliclazide\n\nBlood Sugar Control\n\nGliclazide effectively lowers blood glucose levels by increasing insulin secretion.\nHelps prevent complications associated with diabetes, such as neuropathy, nephropathy, and retinopathy.\nReduced Risk of Hypoglycemia\n\nCompared to some other sulfonylureas, Gliclazide has a lower risk of causing hypoglycemia (low blood sugar levels).\nIt provides a balanced approach to managing blood sugar without causing excessive drops in glucose levels.\nCardiovascular Benefits\n\nStudies suggest that Gliclazide may have a protective effect on the cardiovascular system.\nIt may reduce the risk of cardiovascular events in diabetic patients, promoting overall heart health.\nImproved Glycemic Control\n\nHelps achieve and maintain target HbA1c levels, reflecting long-term glycemic control.\nCan be used in combination with other oral antidiabetic agents or insulin to enhance its effectiveness.\nUsage and Dosage\nGLICLAGLAZE 80 should be taken as prescribed by a healthcare professional. The typical starting dose is 40 to 80 mg daily, which can be adjusted based on the patient's blood glucose response. It is usually taken with meals to maximize its effectiveness and minimize gastrointestinal side effects. Consistent use and adherence to prescribed dosage are crucial for optimal results.\n\nIndications for Use\n\nType 2 Diabetes Mellitus: GLICLAGLAZE 80 is indicated for the management of type 2 diabetes in patients who cannot achieve adequate glycemic control through diet and exercise alone.\nCombination Therapy: It can be used in conjunction with other oral hypoglycemic agents or insulin to achieve better blood sugar control.\nSide Effects\nGLICLAGLAZE 80 is generally well-tolerated. However, some patients may experience side effects, including:\n\nHypoglycemia: Although less common, low blood sugar can occur, especially if meals are skipped or combined with excessive physical activity.\nGastrointestinal Issues: Nausea, abdominal pain, and diarrhea may occur but are usually mild and transient.\nAllergic Reactions: Rarely, allergic reactions such as skin rash, itching, or hives may occur.\nPrecautions and Contraindications\n\nLiver and Kidney Impairment: Patients with severe liver or kidney disease should use GLICLAGLAZE 80 with caution, as it may require dose adjustments.\nPregnancy and Lactation: Gliclazide is not recommended during pregnancy or breastfeeding. Alternative treatments should be considered.\nDrug Interactions: Inform your healthcare provider about all medications and supplements you are taking, as Gliclazide can interact with other drugs, potentially altering its effectiveness.\nConclusion\nGLICLAGLAZE 80 is a reliable and effective oral medication for managing type 2 diabetes mellitus. By stimulating insulin secretion, it helps control blood sugar levels, reducing the risk of diabetes-related complications. Its balanced approach to glycemic control, combined with potential cardiovascular benefits, makes GLICLAGLAZE 80 a valuable addition to diabetes management plans. Under the guidance of a healthcare professional, GLICLAGLAZE 80 can significantly improve the quality of life for individuals with type 2 diabetes, promoting better long-term health outcomes.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 265.0, "discountamount": 79.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "skin rash", "lower risk", "40 to 80 mg", "other drugs", "severe liver", "Reduced Risk", "Consistent use", "kidney disease", "abdominal pain", "excessive drops", "optimal results", "dose adjustments", "diabetic patients", "insulin secretion", "valuable addition", "Drug Interactions", "Kidney Impairment", "protective effect", "balanced approach", "Allergic Reactions", "healthcare provider", "Combination Therapy", "other sulfonylureas", "Blood Sugar Control", "target HbA1c levels", "overall heart health", "cardiovascular events", "cardiovascular system", "typical starting dose", "pancreatic beta cells", "Alternative treatments", "blood glucose response", "low blood sugar levels", "healthcare professional", "Gastrointestinal Issues", "type 2 diabetes mellitus", "diabetes management plans", "adequate glycemic control", "effective oral medication", "long-term health outcomes", "oral hypoglycemic therapy", "long-term glycemic control", "effective treatment option", "excessive physical activity", "optimal blood glucose levels", "gastrointestinal side effects", "diabetes-related complications", "other oral hypoglycemic agents", "other oral antidiabetic agents", "potential cardiovascular benefits" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1922, "imageuri": "https://productimages.withfloats.com/actual/668d2505c34ba6457aa3fb4d.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668d2505c34ba6457aa3fb4d.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-09T11:54:39.186Z", "updatedon": "2024-07-09T11:54:39.186Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-80-/1922", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE 80 ", "category": "DIABETIC RANGE", "tags": [ "Gliclazide 80mg side effects", "Gliclazide 80mg dosage", "Gliclazide 80mg Metformin 500mg", "Gliclazide 80mg price", "Gliclazide 80mg uses", "Gliclazide 80mg Uses in Hindi", "Gliclazide 80mg before or after meal" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661aea4d91d281c30c76019", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRI GLIBEN FORTE ", "description": "TRI GLIBEN FORTE \nGlibenclamide (5mg), Metformin HCI (500mg), Pioglitazone (15mg)\nTRI GLIBEN FORTE is a combination medication containing Glibenclamide, Metformin HCI, and Pioglitazone. This combination is commonly prescribed for the management of type 2 diabetes mellitus, a condition characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nGlibenclamide (5mg): Glibenclamide belongs to the sulfonylurea class of medications. It works by stimulating the pancreas to release insulin, thereby lowering blood sugar levels. Glibenclamide also helps the body use insulin more effectively.\n\nMetformin HCI (500mg): Metformin is a biguanide medication that reduces glucose production in the liver, decreases intestinal glucose absorption, and enhances insulin sensitivity in peripheral tissues. It is a first-line treatment for type 2 diabetes and helps improve overall glycemic control.\n\nPioglitazone (15mg): Pioglitazone is a thiazolidinedione medication that improves insulin sensitivity in muscle and adipose (fat) tissues. It reduces glucose production in the liver and enhances glucose uptake in peripheral tissues, leading to better blood sugar control.\n\nKey Benefits of TRI GLIBEN FORTE:\nComprehensive Glucose Control: The combination of Glibenclamide, Metformin HCI, and Pioglitazone targets multiple pathways involved in glucose metabolism, providing comprehensive control over blood sugar levels.\n\nStimulates Insulin Release: Glibenclamide stimulates insulin secretion from the pancreas, especially after meals, helping to regulate postprandial (after-meal) glucose spikes.\n\nImproves Insulin Sensitivity: Metformin and Pioglitazone improve insulin sensitivity in cells, allowing for better utilization of glucose and reducing insulin resistance.\n\nReduces Hepatic Glucose Production: Metformin and Pioglitazone both reduce the production of glucose in the liver, helping to lower fasting blood sugar levels.\n\nCardiometabolic Benefits: Pioglitazone may have additional benefits for cardiovascular health, such as reducing inflammation and improving lipid profiles.\n\nDosage and Administration:\nThe typical dosage of TRI GLIBEN FORTE is one tablet taken orally once or twice daily, as prescribed by your healthcare provider.\nIt is usually taken with meals to reduce the risk of gastrointestinal side effects.\nFollow your doctor's instructions regarding dosage adjustments based on your blood sugar levels and response to treatment.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/tri-gliben-forte-133450", "price": 74.0, "discountamount": 22.2, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "body", "risk", "Order", "500mg", "EMAIL", "liver", "meals", "cells", "muscle", "doctor", "adipose", "response", "pancreas", "condition", "management", "one tablet", "utilization", "information", "medications", "Pioglitazone", "sterispharma", "Key Benefits", "fat) tissues", "instructions", "postprandial", "inflammation", "sterisonline", "CALL/WHATSAPP", "Metformin HCI", "Glibenclamide", "Administration", "typical dosage", "glucose uptake", "lipid profiles", "Insulin Release", "TRI GLIBEN FORTE", "insulin secretion", "multiple pathways", "dosage adjustments", "glucose metabolism", "peripheral tissues", "sulfonylurea class", "insulin resistance", "blood sugar control", "healthcare provider", "insulin sensitivity", "additional benefits", "biguanide medication", "first-line treatment", "meal) glucose spikes", "cardiovascular health", "comprehensive control", "combination medication", "high blood sugar levels", "overall glycemic control", "Cardiometabolic Benefits", "type 2 diabetes mellitus", "Hepatic Glucose Production", "thiazolidinedione medication", "intestinal glucose absorption", "Comprehensive Glucose Control", "gastrointestinal side effects", "inadequate insulin production" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1483, "imageuri": "https://productimages.withfloats.com/actual/6661aea6dd39d2ccddbc8e54.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661aea6dd39d2ccddbc8e54.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:42:12.134Z", "updatedon": "2024-06-28T12:16:49.307Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//tri-gliben-forte-/1483", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRI GLIBEN FORTE ", "category": "DIABETIC RANGE", "tags": [ "TRI GLIBEN FORTE", "Glibenclamide (5mg)", "Metformin HCI (500mg)", "Pioglitazone (15mg)", "Pioglitazone 15 mg uses", "Pioglitazone side effects", "Pioglitazone uses" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661adf866170d1ff8cb45d2", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PM 500 ", "description": "TENELIGOLD PM 500 \nTeneligliptin 20mg, Pioglitazone 15mg & Extended Release Metformin Hydrochloride 500mg\nTENELIGOLD PM 500 is a combination medication containing Teneligliptin, Pioglitazone, and Extended-Release Metformin Hydrochloride. It is primarily prescribed for the management of type 2 diabetes mellitus, a metabolic disorder characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nTeneligliptin (20mg): Teneligliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It works by inhibiting the DPP-4 enzyme, which enhances the levels of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones stimulate insulin secretion and inhibit glucagon release, leading to improved glucose control after meals.\n\nPioglitazone (15mg): Pioglitazone is a thiazolidinedione medication that improves insulin sensitivity in muscle and adipose (fat) tissues. It reduces glucose production in the liver and enhances glucose uptake in peripheral tissues. This action helps lower blood sugar levels and improves overall glycemic control.\n\nExtended-Release Metformin Hydrochloride (500mg): Metformin is a biguanide medication that reduces glucose production in the liver, decreases intestinal glucose absorption, and enhances insulin sensitivity in peripheral tissues. Extended-release formulations provide a sustained release of the drug, allowing for once-daily dosing and potentially reducing gastrointestinal side effects.\n\nKey Benefits of TENELIGOLD PM 500:\nComprehensive Glycemic Control: The combination of Teneligliptin, Pioglitazone, and Extended-Release Metformin offers comprehensive control over fasting and postprandial (after-meal) blood sugar levels.\n\nImproved Insulin Sensitivity: Pioglitazone and Metformin work synergistically to improve insulin sensitivity in cells, leading to better utilization of glucose and reduced insulin resistance.\n\nIncretin Hormone Enhancement: Teneligliptin enhances the action of incretin hormones, which regulate insulin secretion and glucagon levels, resulting in improved glucose regulation after meals.\n\nReduced Side Effects: Extended-release formulations of Metformin may reduce gastrointestinal side effects compared to immediate-release formulations.\n\nDosage and Administration:\nThe typical dosage of TENELIGOLD PM 500 is one tablet taken orally once daily, preferably with meals.\nSwallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nFollow your doctor's instructions regarding dosage adjustments based on your medical condition and response to treatment.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-pm-500-134300", "price": 180.0, "discountamount": 54.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "meals", "500mg", "EMAIL", "cells", "drugs", "GLP-1", "liver", "glass", "water", "dosing", "muscle", "action", "doctor", "fasting", "response", "treatment", "management", "one tablet", "utilization", "information", "postprandial", "Pioglitazone", "Key Benefits", "fat) tissues", "sterisonline", "sterispharma", "instructions", "DPP-4 enzyme", "CALL/WHATSAPP", "TENELIGOLD PM", "Teneligliptin", "glucose uptake", "Administration", "typical dosage", "glucose control", "glucagon levels", "glucagon release", "incretin hormones", "insulin secretion", "sustained release", "medical condition", "dosage adjustments", "metabolic disorder", "glucose regulation", "peripheral tissues", "insulin resistance", "glucose production", "healthcare provider", "insulin sensitivity", "biguanide medication", "Reduced Side Effects", "comprehensive control", "combination medication", "DPP-4) inhibitor class", "dipeptidyl peptidase-4", "high blood sugar levels", "overall glycemic control", "type 2 diabetes mellitus", "meal) blood sugar levels", "Incretin Hormone Enhancement", "thiazolidinedione medication", "Extended-release formulations", "inadequate insulin production", "intestinal glucose absorption", "gastrointestinal side effects", "Comprehensive Glycemic Control", "immediate-release formulations", "Extended-Release Metformin Hydrochloride", "glucose-dependent insulinotropic peptide", "Extended Release Metformin Hydrochloride" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1481, "imageuri": "https://productimages.withfloats.com/actual/6661adfd637f8700d7ca4512.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661adfd637f8700d7ca4512.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:39:20.713Z", "updatedon": "2024-06-28T12:21:18.417Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//teneligold-pm-500-/1481", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PM 500 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD PM 500", "Teneligliptin 20mg", "Pioglitazone 15mg", "Metformin Hydrochloride 500mg", "Teneligliptin Tablets 20 mg uses", "Teneligliptin 20 mg + Metformin 500", "Teneligliptin 20 mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661ad3166170d1ff8cb4574", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nTENELIGOLD PIO 20/15 is a combination medication that contains Teneligliptin and Pioglitazone. It is primarily used in the management of type 2 diabetes mellitus, a condition characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nTeneligliptin: Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting the DPP-4 enzyme, which in turn enhances the levels of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones stimulate insulin secretion and inhibit glucagon release, leading to improved glucose control after meals.\n\nPioglitazone: Pioglitazone belongs to the thiazolidinedione class of medications. It works by improving insulin sensitivity in muscle and adipose (fat) tissues, reducing glucose production in the liver, and enhancing glucose uptake in peripheral tissues. This helps lower blood sugar levels and improves overall glycemic control.\n\nBenefits of TENELIGOLD PIO 20/15:\nComprehensive Glycemic Control: The combination of Teneligliptin and Pioglitazone addresses different aspects of glucose metabolism, providing comprehensive control over fasting and postprandial (after-meal) blood sugar levels.\n\nEnhanced Insulin Sensitivity: Pioglitazone improves insulin sensitivity in cells, allowing better utilization of glucose and reducing insulin resistance.\n\nIncretin Hormone Enhancement: Teneligliptin enhances the action of incretin hormones, which regulate insulin secretion and glucagon levels, leading to better glucose regulation after meals.\n\nCardioprotective Effects: Pioglitazone has been associated with cardiovascular benefits such as improved lipid profiles and reduced risk of cardiovascular events in some patients.\n\nHow to Use TENELIGOLD PIO 20/15:\nDosage: The typical dosage is one tablet taken orally once daily, usually with meals. Your healthcare provider will determine the appropriate dosage based on your medical condition and response to treatment.\n\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your doctor.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-pio-20-15-134077", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "risk", "turn", "Order", "EMAIL", "GLP-1", "water", "glass", "meals", "cells", "liver", "action", "muscle", "doctor", "adipose", "fasting", "patients", "response", "treatment", "one tablet", "management", "information", "medications", "utilization", "Pioglitazone", "postprandial", "fat) tissues", "DPP-4 enzyme", "sterispharma", "sterisonline", "CALL/WHATSAPP", "Teneligliptin", "teneligold-pio", "glucose uptake", "lipid profiles", "typical dosage", "Administration", "TENELIGOLD PIO", "glucagon levels", "glucose control", "glucagon release", "DPP-4) inhibitor", "incretin hormones", "medical condition", "different aspects", "insulin secretion", "glucose production", "insulin resistance", "appropriate dosage", "glucose metabolism", "glucose regulation", "peripheral tissues", "healthcare provider", "cardiovascular events", "comprehensive control", "combination medication", "dipeptidyl peptidase-4", "thiazolidinedione class", "cardiovascular benefits", "high blood sugar levels", "Cardioprotective Effects", "overall glycemic control", "type 2 diabetes mellitus", "meal) blood sugar levels", "Enhanced Insulin Sensitivity", "Incretin Hormone Enhancement", "inadequate insulin production", "Comprehensive Glycemic Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1480, "imageuri": "https://productimages.withfloats.com/actual/6661ad34c749b7962dbc4345.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661ad34c749b7962dbc4345.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:36:01.592Z", "updatedon": "2024-06-28T12:39:29.014Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1480", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD PIO 20/15", "Teneligliptin", "Pioglitazone", "Teneligliptin uses", "Teneligliptin side effects", "Teneligliptin 20mg", "Teneligliptin+Metformin", "Teneligliptin 20 mg price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }